Form 4: Arcus Biosciences COO Jennifer Jarrett Receives Stock Options and Restricted Stock Units

Arcus Biosciences' Chief Operating Officer, Jennifer Jarrett, was granted 200,000 stock options and 50,000 restricted stock units on January 23, 2025.

Summary

• Jennifer Jarrett, the Chief Operating Officer of Arcus Biosciences, received 200,000 stock options and 50,000 restricted stock units on January 23, 2025.
• The stock options have an exercise price of $13.33 and become exercisable in 48 equal monthly installments after January 1, 2025, with an expiration date of January 22, 2035.
• The restricted stock units vest in four equal annual installments beginning December 15, 2025, contingent upon Ms. Jarrett's continued service to the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative sentiment.

Positives

• The grant of stock options and restricted stock units aligns the COO's interests with those of the shareholders.
• The vesting schedule for both the options and restricted stock units encourages long-term commitment from the COO.

Risks

• The value of the stock options and restricted stock units is dependent on the future performance of Arcus Biosciences' stock price.
• If Ms. Jarrett leaves the company before the vesting periods are complete, she may forfeit some or all of the unvested options and units.

Future Outlook

The vesting of the stock options and restricted stock units is contingent upon the continued service of the COO, suggesting an expectation of her long-term involvement with the company.

Industry Context

The granting of stock options and restricted stock units is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants and restricted stock units are standard compensation practices for executives in the biotech industry, similar to companies like Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN).
• The vesting schedules are also typical, with monthly vesting for options and annual vesting for restricted stock units, aligning with industry norms for long-term incentive plans.

Stakeholder Impact

• Shareholders may view the grants positively as they incentivize the COO to work towards increasing the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, insider trading, Arcus Biosciences, RCUS, Jennifer Jarrett, COO